{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:35Z","timestamp":1792788215327,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Copenhagen University","id":[{"id":"https:\/\/ror.org\/035b05819","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-026-01178-0","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:06:11Z","timestamp":1782846371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Meta-analysis of clinical trials assessing the safety of pharmacological treatments for muscular degeneration in Duchenne muscular dystrophy"],"prefix":"10.1186","volume":"27","author":[{"given":"Gerard","family":"Ompad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra Maria","family":"Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Sonne","family":"Heckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Olmastroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Casula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"3","key":"1178_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251\u201367.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1178_CR2","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","volume":"24","author":"JK Mah","year":"2014","unstructured":"Mah JK, Korngut L, Dykeman J, et al. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014;24(6):482\u201391.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"1178_CR3","doi-asserted-by":"publisher","first-page":"e12914","DOI":"10.1111\/nan.12914","volume":"49","author":"C Pascual-Morena","year":"2023","unstructured":"Pascual-Morena C, Cavero\u2010Redondo I, Sequ\u00ed\u2010Dom\u00ednguez I, et al. Intelligence quotient\u2013genotype association in dystrophinopathies: A systematic review and meta\u2010analysis. Neuropathol Appl Neurobiol. 2023;49(3):e12914.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"1178_CR4","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s41467-025-56644-w","volume":"16","author":"C Vaillend","year":"2025","unstructured":"Vaillend C, Aoki Y, Mercuri E, et al. Duchenne muscular dystrophy: recent insights in brain related comorbidities. Nat Commun. 2025;16(1):1298.","journal-title":"Nat Commun"},{"issue":"4","key":"1178_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347\u201361.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1178_CR6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/ppul.25111","volume":"56","author":"DJ Birnkrant","year":"2021","unstructured":"Birnkrant DJ, Carter JC. Cardiopulmonary phenotypic variability and discordance in Duchenne muscular dystrophy: implications for new therapies. Pediatr Pulmonol. 2021;56(4):738\u201346.","journal-title":"Pediatr Pulmonol"},{"key":"1178_CR7","doi-asserted-by":"crossref","unstructured":"Wang M, Birnkrant DJ, Super DM, et al. Progressive left ventricular dysfunction and long-term outcomes in patients with Duchenne muscular dystrophy receiving cardiopulmonary therapies. Open Heart. 2018;5(1).","DOI":"10.1136\/openhrt-2018-000783"},{"issue":"6","key":"1178_CR8","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40272-024-00655-5","volume":"26","author":"C Pascual-Morena","year":"2024","unstructured":"Pascual-Morena C, Lucer\u00f3n-Lucas-Torres M, Martinez-Garcia I, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a systematic review. Pediatr Drugs. 2024;26(6):695\u2013707.","journal-title":"Pediatr Drugs"},{"issue":"6","key":"1178_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000547936","volume":"110","author":"P Das","year":"2025","unstructured":"Das P, Ojha B, Das A, et al. Safety and Efficacy of Givinostat for patients with Muscular dystrophy: A Systematic review. Pharmacology. 2025;110(6):347\u201359.","journal-title":"Pharmacology"},{"issue":"8","key":"1178_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00439-025-02758-6","volume":"144","author":"C Pascual-Morena","year":"2025","unstructured":"Pascual-Morena C, Pati\u00f1o-Cardona S, Martinez-Garcia I, et al. Efficacy of delandistrogene moxeparvovec on Duchenne muscular dystrophy: a systematic review and meta-analysis. Hum Genet. 2025;144(8):795\u2013807.","journal-title":"Hum Genet"},{"issue":"20","key":"1178_CR11","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","volume":"87","author":"RC Griggs","year":"2016","unstructured":"Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87(20):2123\u201331.","journal-title":"Neurology"},{"issue":"1","key":"1178_CR12","doi-asserted-by":"publisher","first-page":"e2144178","DOI":"10.1001\/jamanetworkopen.2021.44178","volume":"5","author":"JK Mah","year":"2022","unstructured":"Mah JK, Clemens PR, Guglieri M, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial. JAMA Netw open. 2022;5(1):e2144178.","journal-title":"JAMA Netw open"},{"issue":"1","key":"1178_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/mus.26736","volume":"61","author":"CM McDonald","year":"2020","unstructured":"McDonald CM, Sajeev G, Yao Z, et al. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle Nerve. 2020;61(1):26\u201335.","journal-title":"Muscle Nerve"},{"issue":"5","key":"1178_CR14","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/mus.26191","volume":"58","author":"PB Shieh","year":"2018","unstructured":"Shieh PB, Mcintosh J, Jin F, et al. Deflazacort versus prednisone\/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial. Muscle Nerve. 2018;58(5):639\u201345.","journal-title":"Muscle Nerve"},{"issue":"3","key":"1178_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/hmg\/ddad173","volume":"33","author":"G Liu","year":"2024","unstructured":"Liu G, Lipari P, Mollin A, et al. Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models. Hum Mol Genet. 2024;33(3):211\u201323.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"1178_CR16","doi-asserted-by":"publisher","first-page":"e208112","DOI":"10.1212\/WNL.0000000000208112","volume":"102","author":"UJ Dang","year":"2024","unstructured":"Dang UJ, Damsker JM, Guglieri M, et al. Efficacy and safety of vamorolone over 48 weeks in boys with Duchenne muscular dystrophy: a randomized controlled trial. Neurology. 2024;102(5):e208112.","journal-title":"Neurology"},{"key":"1178_CR17","doi-asserted-by":"crossref","unstructured":"Naarding KJ, Stimpson G, Ward SJ, et al. 269th ENMC international workshop: 10 years of clinical trials in Duchenne muscular dystrophy\u2013What have we learned? 9\u201311 December 2022, Hoofddorp, The Netherlands. Neuromuscular Disorders. 2023;33(11):897\u2013910.","DOI":"10.1016\/j.nmd.2023.10.003"},{"key":"1178_CR18","doi-asserted-by":"crossref","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366.","DOI":"10.1136\/bmj.l4898"},{"issue":"10","key":"1178_CR19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","volume":"79","author":"M Guglieri","year":"2022","unstructured":"Guglieri M, Clemens PR, Perlman SJ, et al. Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial. Jama Neurol. 2022;79(10):1005\u201314.","journal-title":"Jama Neurol"},{"issue":"4","key":"1178_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","volume":"23","author":"E Mercuri","year":"2024","unstructured":"Mercuri E, Vilchez JJ, Boespflug-Tanguy O, et al. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024;23(4):393\u2013403.","journal-title":"Lancet Neurol"},{"key":"1178_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejpn.2022.04.004","volume":"38","author":"C Reddy","year":"2022","unstructured":"Reddy C, Patil AN, Suthar R, et al. Deflazacort dose optimization and safety evaluation in Duchenne muscular dystrophy (DOSE): A randomized, double-blind non-inferiority trial. Eur J Pediatr Neurol. 2022;38:77\u201384.","journal-title":"Eur J Pediatr Neurol"},{"issue":"15","key":"1178_CR22","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2022.4315","volume":"327","author":"M Guglieri","year":"2022","unstructured":"Guglieri M, Bushby K, McDermott MP, et al. Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy: a randomized clinical trial. JAMA. 2022;327(15):1456\u201368.","journal-title":"JAMA"},{"issue":"1","key":"1178_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/mus.27428","volume":"65","author":"GS Kochar","year":"2022","unstructured":"Kochar GS, Sondhi V, Kabra SK, et al. Intermittent versus daily regimen of prednisolone in ambulatory boys with Duchenne muscular dystrophy: A randomized, open-label trial. Muscle Nerve. 2022;65(1):60\u20136.","journal-title":"Muscle Nerve"},{"issue":"6","key":"1178_CR24","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/mus.26441","volume":"59","author":"AM Connolly","year":"2019","unstructured":"Connolly AM, Zaidman CM, Golumbek PT, et al. Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy. Muscle Nerve. 2019;59(6):650\u20137.","journal-title":"Muscle Nerve"},{"issue":"9","key":"1178_CR25","doi-asserted-by":"publisher","first-page":"e1003222","DOI":"10.1371\/journal.pmed.1003222","volume":"17","author":"EC Smith","year":"2020","unstructured":"Smith EC, Conklin LS, Hoffman EP, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. PLoS Med. 2020;17(9):e1003222.","journal-title":"PLoS Med"},{"key":"1178_CR26","unstructured":"Phase A. II Open-label, multicenter extension study to assess the long-term safety and efficacy of vamorolone in boys with duchenne muscular dystrophy (DMD) [Internet]. 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02760277"},{"key":"1178_CR27","unstructured":"Phase IIa A. Open-label, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of vamorolone in boys with duchenne muscular dystrophy (DMD) [Internet]. 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02760264"},{"issue":"10","key":"1178_CR28","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","volume":"26","author":"P Bettica","year":"2016","unstructured":"Bettica P, Petrini S, D\u2019Oria V, et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26(10):643\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"1178_CR29","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/mus.24665","volume":"52","author":"J Hu","year":"2015","unstructured":"Hu J, Ye Y, Kong M, et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle Nerve. 2015;52(6):1001\u20137.","journal-title":"Muscle Nerve"},{"issue":"1","key":"1178_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13018-022-02996-8","volume":"17","author":"N Salari","year":"2022","unstructured":"Salari N, Fatahi B, Valipour E, et al. Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis. J Orthop Surg Res. 2022;17(1):96.","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"1178_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","volume":"96","author":"H Sch\u00e4cke","year":"2002","unstructured":"Sch\u00e4cke H, D\u00f6cke W-D, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23\u201343.","journal-title":"Pharmacol Ther"},{"issue":"10","key":"1178_CR32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2165\/00002018-200730100-00005","volume":"30","author":"L Fardet","year":"2007","unstructured":"Fardet L, Kassar A, Cabane J, et al. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf. 2007;30(10):861\u201381.","journal-title":"Drug Saf"},{"issue":"5","key":"1178_CR33","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s10072-024-07939-1","volume":"46","author":"MS Ibrahim","year":"2025","unstructured":"Ibrahim MS, Abdelwahab OA, Elawfi B, et al. Meta-analysis of the efficacy and safety of vamorolone in Duchenne muscular dystrophy. Neurol Sci. 2025;46(5):2249\u201362.","journal-title":"Neurol Sci"},{"key":"1178_CR34","unstructured":"Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. 2023."},{"issue":"4","key":"1178_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.nmd.2006.01.010","volume":"16","author":"W Biggar","year":"2006","unstructured":"Biggar W, Harris V, Eliasoph L, et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006;16(4):249\u201355.","journal-title":"Neuromuscul Disord"},{"key":"1178_CR36","doi-asserted-by":"crossref","unstructured":"Matthews E, Brassington R, Kuntzer T, et al. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews; 2016.","DOI":"10.1002\/14651858.CD003725.pub4"},{"issue":"5","key":"1178_CR37","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40271-022-00574-y","volume":"15","author":"NL Crossnohere","year":"2022","unstructured":"Crossnohere NL, Fischer R, Vroom E, et al. A comparison of caregiver and patient preferences for treating Duchenne muscular dystrophy. Patient. 2022;15(5):577.","journal-title":"Patient"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01178-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01178-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01178-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:04:47Z","timestamp":1790172287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-026-01178-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1178"],"URL":"https:\/\/doi.org\/10.1186\/s40360-026-01178-0","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"130"}}